1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 22 FEBRUARY 2016

Cancer Drug News 22 FEBRUARY 2016

  • February 2016
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Stage Set For Next Checkpoint Inhibitor Battle
Industry Trend Analysis - Ibrance Earnings Potential Unlocked Further
Industry Brief - OBI-822/821 Phase II/III Trial Fails To Meet Primary Endpoint In MBC
Industry Brief - Novartis' PKC412 Granted FDA Breakthrough Therapy Status For AML Subtype
Industry Trend Analysis - CAR-T Validation Increasing Confidence
Industry Brief - Aranesp Phase III Study Meets Primary Endpoint In MDS Patients
Industry Brief - Apogenix Secures Funding To Develop APG101 For Glioblastoma
Industry Brief - eFFECTOR Increases Funds To Advance Anti-Cancer Candidate
Industry Trend Analysis - National Cancer Moonshot Mirrors Current Oncology Trends
Industry Brief - BMS/Dana-Farber Cancer Institute Collaborate On I-O RPM Programme
Industry Brief - Myriad Collaborates With Tesaro/Merck On Companion Diagnostic Research
Industry Brief - Helsinn/Mundipharma Enter Deal For Anamorelin In Northern Europe
Industry Brief - Cancer Conferences - May 2016

Table Of Contents

Cancer Drug News 22 FEBRUARY 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 10 125
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6 650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.